About this trial
The purpose of this study is to determine whether the drug nivolumab can improve overall survival, disease-free survival, or both compared with placebo treatment in patients with residual disease after CRT and surgery.
This study is open to men and women over 18 years of age with confirmed cancer of the oesophagus, or the junction between the oesophagus and the stomach (oesophago-gastric juncion, OGJ) cancer who have previously received chemoradiotherapy (CRT) treatment followed by surgery.
Patients should have had stage II or III disease but have been diagnosed with residual pathologic disease after being surgically rendered free of disease with negative margins following complete resection.
Where’s this trial being run?Beaumont Hospital, Cork University Hospital, and University Hospital Galway
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
A Randomized, multicenter, double blind, phase III study of adjuvant nivolumab or placebo in patients with resected lower oesophageal, or gastroesophageal junction cancer.
|Principal Investigator:||Dr Patrick Morris|
Global: July 2016
Ireland: November 2016
|Global Recruitment Target:||760|
|Ireland Recruitment Target:||12|